Shares of Translate Bio Inc (NASDAQ:TBIO) were up 5.2% during mid-day trading on Monday . The company traded as high as $8.89 and last traded at $8.77, approximately 104,995 shares were traded during trading. A decline of 56% from the average daily volume of 236,065 shares. The stock had previously closed at $8.34.
A number of equities analysts recently issued reports on TBIO shares. Zacks Investment Research upgraded shares of Translate Bio from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Translate Bio in a research report on Thursday, August 1st. Citigroup set a $17.00 price objective on shares of Translate Bio and gave the stock a “buy” rating in a research report on Tuesday, September 10th. ValuEngine upgraded shares of Translate Bio from a “sell” rating to a “hold” rating in a research report on Sunday, October 13th. Finally, Jefferies Financial Group started coverage on shares of Translate Bio in a research report on Monday, July 22nd. They set a “buy” rating and a $20.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Translate Bio has a consensus rating of “Buy” and an average target price of $21.60.
The stock’s 50-day moving average is $9.63 and its 200-day moving average is $9.88. The firm has a market capitalization of $447.36 million, a price-to-earnings ratio of -2.41 and a beta of 0.92. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 1.15.
Translate Bio (NASDAQ:TBIO) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.09). The company had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.73 million. Translate Bio had a negative return on equity of 84.22% and a negative net margin of 2,696.98%. On average, equities research analysts anticipate that Translate Bio Inc will post -1.96 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in TBIO. Bank of Montreal Can acquired a new position in Translate Bio during the 2nd quarter worth approximately $31,000. Metropolitan Life Insurance Co NY bought a new stake in Translate Bio during the 1st quarter worth approximately $119,000. Susquehanna International Group LLP bought a new stake in Translate Bio during the 2nd quarter worth approximately $147,000. MetLife Investment Advisors LLC bought a new stake in Translate Bio during the 1st quarter worth approximately $165,000. Finally, Wells Fargo & Company MN grew its holdings in Translate Bio by 30.5% during the 2nd quarter. Wells Fargo & Company MN now owns 14,532 shares of the company’s stock worth $183,000 after acquiring an additional 3,393 shares during the last quarter. Institutional investors and hedge funds own 72.68% of the company’s stock.
Translate Bio Company Profile (NASDAQ:TBIO)
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.